Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
J Med Virol. 2020 Aug;92(8):1355-1358. doi: 10.1002/jmv.25692. Epub 2020 Feb 7.
Adherence to nucleotide/nucleoside analog therapy is important in improving prognosis in chronic hepatitis B. We aimed to compare medical adherence and satisfaction with entecavir (ETV) and tenofovir alafenamide (TAF) and to assess the effect of switching from ETV to TAF. Patients taking ETV (n = 114) and TAF (n = 35), and who switched from ETV to TAF (n = 15) were included. Medication adherence and satisfaction were assessed using a questionnaire. There was no significant difference in adherence between the ETV and TAF groups, but the medication satisfaction rates (0-10, prefer-dislike) were 1.72 ± 2.2 and 0.69 ± 1.5, respectively (P = .01; significantly higher in the TAF group). In patients who switched from ETV to TAF, medication adherence significantly improved (P = .04) as follows: never forgetting, from 40% to 87%; forgetting once every 2 to 3 months, from 33% to 7%; forgetting once every 2 months, from 20% to 7%, and forgetting once every 4 weeks, from 7% to 0%. Similarly, the medication satisfaction rate significantly improved from 4.53 ± 3.2 to 1.27 ± 2.4 after switching (P = .008). In conclusion, switching from ETV to TAF can be a useful approach to improve medication adherence and satisfaction.
核苷（酸）类似物治疗的依从性对于改善慢性乙型肝炎的预后非常重要。我们旨在比较恩替卡韦（ETV）和替诺福韦艾拉酚胺（TAF）的用药依从性和满意度，并评估从 ETV 转换为 TAF 的效果。纳入了服用 ETV（n=114）和 TAF（n=35）的患者，以及从 ETV 转换为 TAF 的患者（n=15）。使用问卷评估药物依从性和满意度。ETV 和 TAF 组之间的依从性没有显著差异，但药物满意度评分（0-10，喜欢-不喜欢）分别为 1.72±2.2 和 0.69±1.5（P=0.01，TAF 组显著更高）。从 ETV 转换为 TAF 的患者，药物依从性显著改善（P=0.04）如下：从不忘记，从 40%增加到 87%；每 2-3 个月忘记一次，从 33%增加到 7%；每 2 个月忘记一次，从 20%增加到 7%，每 4 周忘记一次，从 7%降至 0%。同样，转换后药物满意度评分从 4.53±3.2 显著提高到 1.27±2.4（P=0.008）。总之，从 ETV 转换为 TAF 可以有效提高药物依从性和满意度。
